Drug & Supplement Interactions

Psilocybin + Entrectinib

Brand name of Entrectinib

  • Rozlytrek

Medically reviewed by

Also reviewed by the HelloPharmacist Editorial Team

Updated October 2026Details about this page

AI is used only to summarize verified clinical information, never the open internet. Our AI policy

The Bottom Line Best Avoided

We found no known interaction between Psilocybin and Entrectinib in our sources, but our pharmacy team rates Psilocybin itself best avoided. Psilocybin is a controlled substance with powerful mind-altering effects and is not a safe or legal dietary supplement.

This also applies to Rozlytrek, a brand name of entrectinib.

Still Worth Knowing

  • Shared side effects: Although there is no interaction, both can cause some of the same side effects. Taken together, those side effects might add up, and a new symptom can be harder to pin on one or the other.
See the Full Interaction Report

Ask a Question About This Combination

Ask in your own words about taking Psilocybin with Entrectinib. The answer comes from this page’s own records.

Try:

AI answers from this page’s interaction records and our own drug and supplement information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist. How we use AI

Interaction Report

Psilocybin and Entrectinib Interaction Check

No Known Interaction, but Psilocybin Is Best Avoided

We did not find a documented interaction between Entrectinib and Psilocybin in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

Our pharmacy team rates Psilocybin best avoided, whatever else you take. Psilocybin is a controlled substance with powerful mind-altering effects and is not a safe or legal dietary supplement. See Psilocybin’s safety ratings →

How We Checked

Why No Interaction Is Listed for Entrectinib

We sort drugs into categories, such as blood thinners or antibiotics, and many supplement interactions are recorded for a whole category rather than for one drug. So we checked every category Entrectinib is in against every category Psilocybin has a known interaction with.

4Categories Entrectinib Is In
  • Qt Interval-Prolonging Drugs Drugs that can lengthen the QT interval, the part of each heartbeat when the heart recharges, such as some antibiotics, antidepressants and heart rhythm drugs. No Psilocybin Record
  • Hepatotoxic Drugs Drugs that can harm the liver in some people, such as high doses of acetaminophen, isoniazid, methotrexate and valproate. No Psilocybin Record
  • Cytochrome P450 3A4 (Cyp3A4) Substrates Drugs the body breaks down mainly with the liver enzyme CYP3A4; when something slows or speeds up that enzyme, their levels in the blood can rise or fall. No Psilocybin Record
  • Oral Drugs Any drug taken by mouth. No Psilocybin Record
2Drug Categories Psilocybin Interacts With

No overlap. Entrectinib is in none of the 2 categories Psilocybin interacts with, so no record links the two.

Still wondering about combining Psilocybin and Entrectinib? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
Know someone taking this combination? Share
What to Watch For

Side Effects Psilocybin and Entrectinib Have in Common

17 side effects show up for both Psilocybin and Entrectinib.

  • Each has separately been linked to the effects below. Taken together, they might add up: the same side effect from two sources might be more likely or stronger. No study of the two together says by how much.
  • If one turns up, it can be harder to tell which one is behind it, so tell your pharmacist you take both.
  • 4 of them are worth acting on rather than waiting out, marked below.
  • Loss of vision Worth Acting On Additional detail

    Psilocybin

    Orally, single doses of psilocybin have resulted in mild to moderate headache in numerous case studies and experimental studies. Headaches have been reported in up to 50% of individuals, starting a mean of 7 hours after intake and lasting for 1-2 days. Severity and duration seem to be dose-dependent.

    Source: , the clinical database we license.

    6 references cited
    1. 106129. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016;30(12):1181-1197. PubMed
    2. 106131. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018;235(2):399-408. PubMed
    3. 106132. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016;30(12):1165-1180. PubMed
    4. 106134. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016;3(7):619-27. PubMed
    5. 106135. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 2021;78(5):481-489. PubMed
    6. 106137. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015;29(3):289-99. PubMed

    Severe rhabdomyolysis, followed by acute kidney failure and posterior encephalopathy resulting in short-term vision loss, disorientation, agitation, and seizures has been reported in a 25-year-old male following use of an unknown quantity of Psilocybe cubensis mushrooms.

    Source: , the clinical database we license.

    2 references cited
    1. 106181. Bickel M, Ditting T, Watz H, et al. Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuse. Eur J Emerg Med 2005;12(6):306-8. PubMed
    2. 110795. Suleiman M, Basu A, Belal S, Jacob T. From mushrooms to myolysis: A case of rhabdo in psilocybin-induced mood and psychotic disorder. J Nerv Ment Dis 2022;210(8):638-639. PubMed

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section.

    Read Entrectinib’s label on DailyMed ›
  • Hallucinations / Confusion Worth Acting On Additional detail

    Psilocybin

    Psilocybin has psychedelic or hallucinogenic effects, with side effects including visual, auditory, tactile, and other illusions, as well as changes in time and space perception, and "mystical experiences". The severity of some of these responses may be dose-dependent.

    Source: , the clinical database we license.

    6 references cited
    1. 106129. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016;30(12):1181-1197. PubMed
    2. 106137. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015;29(3):289-99. PubMed
    3. 106138. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011;68(1):71-8. PubMed
    4. 106146. Brown RT, Nicholas CR, Cozzi NV, et al. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet 2017;56(12):1543-1554. PubMed
    5. 106150. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial at
    6. 106154. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol 2016;30(12):1268-1278. PubMed

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section.

    Read Entrectinib’s label on DailyMed ›
  • Kidney problems Worth Acting On reported in 3.9% of FDA reports for Entrectinib Additional detail

    Psilocybin

    Recorded for Psilocybin in the same Natural Medicines adverse-effect record shown under Hallucinations / Confusion above.

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section. Voluntary reports to the FDA mention it too.

    Read Entrectinib’s label on DailyMed ›
  • Low mood Worth Acting On Additional detail

    Psilocybin

    Recorded for Psilocybin in the same Natural Medicines adverse-effect record shown under Hallucinations / Confusion above.

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section.

    Read Entrectinib’s label on DailyMed ›
  • Mood changes or irritability Additional detail

    Psilocybin

    Recorded for Psilocybin in the same Natural Medicines adverse-effect record shown under Hallucinations / Confusion above.

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section.

    Read Entrectinib’s label on DailyMed ›
  • Numbness or tingling Additional detail

    Psilocybin

    Orally, single doses of psilocybin have resulted in nausea, and rarely, vomiting and diarrhea. Analysis from a large clinical trial that evaluated single doses of psilocybin 1 mg, 10 mg, and 25 mg suggests that for every 5 patients treated with psilocybin 25 mg over psilocybin 1 mg, one additional case of nausea will occur.

    Source: , the clinical database we license.

    6 references cited
    1. 106129. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016;30(12):1181-1197. PubMed
    2. 106131. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018;235(2):399-408. PubMed
    3. 106132. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016;30(12):1165-1180. PubMed
    4. 106134. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016;3(7):619-27. PubMed
    5. 106137. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015;29(3):289-99. PubMed
    6. 106161. Carbonaro TM, Johnson MW, Griffiths RR. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology (Berl) 2020;237(8):2293-2304. PubMed

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section.

    Read Entrectinib’s label on DailyMed ›
  • Drowsiness Additional detail

    Psilocybin

    Recorded for Psilocybin in the same Natural Medicines adverse-effect record shown under Loss of vision above.

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section.

    Read Entrectinib’s label on DailyMed ›
  • Anxiety or restlessness Additional detail

    Psilocybin

    Recorded for Psilocybin in the same Natural Medicines adverse-effect record shown under Hallucinations / Confusion above.

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section.

    Read Entrectinib’s label on DailyMed ›
  • Reduced appetite Additional detail

    Psilocybin

    Orally, psilocybin in a single dose of 315 mcg/kg resulted in increased levels of thyroid stimulating hormone, prolactin, cortisol, and adrenocorticotropic hormone. The effects of lower doses of psilocybin are unclear.

    Orally, psilocybin in a single dose of 25 mg has resulted in decreased libido in a single case and transient asymptomatic hypoglycemia in 2 adult females with anorexia nervosa.

    Source: , the clinical database we license.

    3 references cited
    1. 106157. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 2004;172(2):145-56. PubMed
    2. 110800. Schneier FR, Feusner J, Wheaton MG, et al. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J Psychiatr Res. 2023;161:364-370. PubMed
    3. 113870. Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med 2023;29(8):1947-1953. PubMed

    Entrectinib

    Source: Entrectinib’s

    It lists this side effect in its Adverse Reactions section.

    Read Entrectinib’s label on DailyMed ›

Showing the 10 most notable of 17 shared effects — ranked by how unusual each one is, not just whether both lists mention it.

Reported for Psilocybin but not commonly for Entrectinib: a heart attack, a slow heartbeat, dependence or withdrawal symptoms and thoughts of self-harm.

Note: Effects for Entrectinib come from the Adverse Reactions section of its FDA label; effects for Psilocybin come from the Natural Medicines adverse-effect record, quoted above. Where a percentage is shown, it is the share of 1,691 voluntary FDA FAERS reports for Entrectinib that mention that effect — a reporting proportion, not an incidence rate and not evidence the drug caused it. The two sources word some effects differently, so we match them by meaning.

If You Already Take Both
  • Tell your pharmacist or doctor that you take Psilocybin, so they can check it against everything else you take.
  • Do not stop a prescribed medicine on your own.
  • Check with your pharmacist or doctor before changing any medicine or supplement, especially if you take several or have an ongoing health condition.

Your Whole Routine

Your Other Medicines and Supplements

Keep It in Perspective

Psilocybin Does Interact With Other Medications

Psilocybin has 293 moderate known drug interactions in our database — Entrectinib isn’t one of them. If you take anything else, check it against the full list below.

Taking Anything Else?

Check Another of Your Medications Against Psilocybin

Covers the 2,830 medications we’ve checked against Psilocybin. Pick one to open its full report.

Alternatives for the Same Use

Other Supplements Studied for Depression, and How They Mix With Entrectinib

Choosing a supplement while you take Entrectinib? Here are other options studied for depression, and whether each has a documented interaction with Entrectinib.

2 of them have a documented interaction with Entrectinib: St. John's Wort (major) and Dhea (moderate).

10 other supplements have at least some evidence of a benefit for depression; the 8 below come first. Psilocybin itself is graded for it.

The grades come from the Natural Medicines database and describe the research so far, not a recommendation, and none of these supplements replaces a prescribed medicine.

Everything Else You Take

See Every Supplement That Interacts With Entrectinib

Take other supplements too? 179 supplements have a documented interaction with Entrectinib, each explained on its page.

By severity: 11 major, 130 moderate and 38 minor.

The Most Serious There Right Now:

Open the Entrectinib interaction pageEvery supplement checked against Entrectinib, ranked by severity

Get to Know Each One

About Psilocybin and Entrectinib

Supplement

About Psilocybin

Psilocybin is a powerful psychedelic compound found in certain mushrooms and is being studied for hard-to-treat depression, anxiety, and addiction, but it is still investigational and not an approved supplement. It is illegal in most places, can cause intense and unpredictable mental effects, and should never be used outside of a supervised clinical setting.

Full Psilocybin guide: uses, dosage, safety and every interaction
Safety at a Glance

How Psilocybin Is Rated

  • Psilocybin Overall

    Avoid

    Psilocybin is a controlled substance with powerful mind-altering effects and is not a safe or legal dietary supplement.

  • Pregnancy

    Avoid

    There is no safety data; avoid during pregnancy.

  • Breastfeeding

    Avoid

    There is no safety data; avoid while breastfeeding.

Medication

About Entrectinib

More to Explore

More Pairs and Interactions to Check

Keep Checking

Other Drugs & Psilocybin

Browse every other medication we’ve checked against Psilocybin — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
293Moderate
0Minor
2,536No known interaction
Moderate

Moderate: 293 interactions

Showing 60 of 293 moderate interactions — see all 293 on the Psilocybin page.

No Interaction 2,536 drugs checked — show the list

We also checked Psilocybin against these medications and found no known interaction in our sources. Open any page to confirm.

Showing 60 of the 2,536 medications checked with no known interaction, the most looked-up first — see the full Psilocybin list.

How Much People Look This Up

Where Psilocybin and Entrectinib Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Psilocybin
Top 25%

#210 of 1,458 supplements looked up here in the last 7 days

29 days ago today
Medication Entrectinib
Top half

#1,159 of 2,830 medications looked up here in the last 7 days

29 days ago today

A rank of lookups on this site, not of how often either one is used. It counts every visit, automated ones included, and identifies no one.

Questions and Sources

Common Questions and Where This Comes From

Pharmacist Counseling Corner

Taking Psilocybin and Entrectinib Together: Common Questions

Can you take Psilocybin with Entrectinib?
We do not list a known interaction between Psilocybin and Entrectinib, but that is not a reason to take Psilocybin: our pharmacy team rates it best avoided, whatever else you take. Psilocybin is a controlled substance with powerful mind-altering effects and is not a safe or legal dietary supplement. Talk with your pharmacist or doctor before taking it, and do not stop or change Entrectinib on your own.
Can you take Psilocybin with Rozlytrek?
Rozlytrek is a brand name of entrectinib, so the answer is the same as for entrectinib. We do not list a known interaction between Psilocybin and Entrectinib, but that is not a reason to take Psilocybin: our pharmacy team rates it best avoided, whatever else you take. Everything on this page applies to Rozlytrek too.
Do Psilocybin and Entrectinib have any of the same side effects?
Yes — our sources link each of them separately to 10 of the same effects. That is not a documented interaction, but taken together the same side effect from two sources might be more likely or stronger; no study of the two together says by how much. And if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
How was the Psilocybin and Entrectinib combination checked?
Interactions in our licensed database are recorded against drug classes. Entrectinib is filed under 4 classifications, and Psilocybin has documented interactions with 2 drug classes — none of Entrectinib's classifications are among them. A medication can belong to classes beyond those recorded in our dataset, so this describes how the check was run rather than guaranteeing safety.
Do other supplements studied for depression interact with Entrectinib?
2 of the 10 other supplements the Natural Medicines database grades as having some evidence of a benefit for depression have a documented interaction with Entrectinib: St. John's Wort (major) and Dhea (moderate). A grade is the research so far, not a recommendation, and no known interaction is not proof of safety; ask your pharmacist before adding one.
Does Psilocybin interact with any other medications?
Yes. Psilocybin has 293 documented drug interactions in our database — Entrectinib is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.
Does Entrectinib interact with any supplements?
Yes. Entrectinib has documented interactions with 179 supplements in our database — Psilocybin is not one of them. The Entrectinib interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist Editorial Team. Our editorial policy

Evidence & Sources

References Cited on This Page

The 16 references the cards above cite, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Show the 16 references
  1. 106129. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016;30(12):1181-1197. PubMed
  2. 106131. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018;235(2):399-408. PubMed
  3. 106132. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016;30(12):1165-1180. PubMed
  4. 106134. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016;3(7):619-27. PubMed
  5. 106135. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 2021;78(5):481-489. PubMed
  6. 106137. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015;29(3):289-99. PubMed
  7. 106138. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011;68(1):71-8. PubMed
  8. 106146. Brown RT, Nicholas CR, Cozzi NV, et al. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet 2017;56(12):1543-1554. PubMed
  9. 106150. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial at
  10. 106154. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol 2016;30(12):1268-1278. PubMed
  11. 106157. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 2004;172(2):145-56. PubMed
  12. 106161. Carbonaro TM, Johnson MW, Griffiths RR. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology (Berl) 2020;237(8):2293-2304. PubMed
  13. 106181. Bickel M, Ditting T, Watz H, et al. Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuse. Eur J Emerg Med 2005;12(6):306-8. PubMed
  14. 110795. Suleiman M, Basu A, Belal S, Jacob T. From mushrooms to myolysis: A case of rhabdo in psilocybin-induced mood and psychotic disorder. J Nerv Ment Dis 2022;210(8):638-639. PubMed
  15. 110800. Schneier FR, Feusner J, Wheaton MG, et al. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J Psychiatr Res. 2023;161:364-370. PubMed
  16. 113870. Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med 2023;29(8):1947-1953. PubMed

All 65 references behind our Psilocybin records are listed in the Psilocybin guide.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is reviewed by the HelloPharmacist Editorial Team. See our data sources and editorial standards.

Where Does Our Data Come From?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 105,612 references behind our interaction content, 67,053 of them resolved to verified PubMed/DOI sources. See the references behind this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified November 15, 2026. The Psilocybin and Entrectinib records this page draws on were last updated October 20, 2026.
Data structure & sourcing designed and verified by .
Rating Key

What Our Interaction Ratings Mean

No interaction is on record for this pair. The other supplements and medicines on this page carry a severity rating: how serious an interaction between them is.

See what each severity means

Severity: How Serious Is It?

How clinically significant the interaction is: how much it could affect your health or your treatment.

  • MajorClinically significant. Best to avoid the combination, or use only under close professional supervision.
  • ModerateBe cautious. The combination may call for monitoring, timing changes, or a dose adjustment.
  • MinorLimited clinical concern, but still worth being aware of and mentioning to your pharmacist.
  • No Known InteractionNo documented interaction in our sources.

Still Have a Question About Psilocybin and Entrectinib?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.